Free tool
FAERS Monitor: Cosopt Pf
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202667 or its brand name (Cosopt Pf, Dorzolamide Hydrochloride, Timolol Maleate). Reports on generic versions are filed under their own applications.
Reports
2,587
Serious
782
30% of reports
Hospitalization
123
Death reported
320
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation513
- ocular hyperaemia453
- eye pruritus308
- drug ineffective256
- eye pain227
- death210
- eye swelling195
- vision blurred139
- lacrimation increased130
- hypersensitivity128
- dyspnoea101
- glaucoma97
- treatment failure95
- bronchitis81
- drug intolerance80
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 12 |
| 2010 | 30 |
| 2011 | 28 |
| 2012 | 17 |
| 2013 | 101 |
| 2014 | 27 |
| 2015 | 7 |
| 2016 | 86 |
| 2017 | 181 |
| 2018 | 187 |
| 2019 | 463 |
| 2020 | 601 |
| 2021 | 283 |
| 2022 | 196 |
| 2023 | 171 |
| 2024 | 62 |
| 2025 | 70 |
| 2026 | 60 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,572 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ocular hyperaemiaSignal | 453 | 78.3 | 72.0 | 34,260 |
| eye pruritusSignal | 308 | 75.2 | 67.7 | 22,307 |
| eye irritationSignal | 513 | 73.1 | 67.6 | 36,187 |
| eye swellingSignal | 195 | 42.8 | 37.4 | 7,898 |
| glaucomaSignal | 97 | 41.2 | 33.8 | 3,746 |
| lacrimation increasedSignal | 130 | 35.1 | 29.7 | 4,264 |
| eye painSignal | 227 | 32.8 | 29.0 | 6,966 |
| treatment failureSignal | 95 | 9.3 | 7.7 | 700 |
| bronchitisSignal | 81 | 8.9 | 7.2 | 562 |
| vision blurredSignal | 139 | 8.2 | 7.0 | 882 |
| drug intoleranceSignal | 80 | 6.7 | 5.4 | 387 |
| hypersensitivitySignal | 128 | 5.6 | 4.7 | 484 |
| death | 210 | 2.0 | 1.7 | 105 |
| drug ineffective | 256 | 1.6 | 1.4 | 57 |
| dyspnoea | 101 | 1.5 | 1.2 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.